David Simon
Chronic heart failure (CHF), which affects a large portion of the global population on a regular basis, frequently progresses to a life-threatening disease, and has a high mortality rate, is another significant global public health issue. We want to find out what progress has been made recently in the care of CHF patients whose left ventricular ejection fraction (LVEF) is below 40%. BNP has been implicated in the aetiology of cardiac disease in recent years. For this reason, we attempted to study the outcomes of the sophisticated medical therapy strategy applied to CHF patients using the combination of sacubitril/alsartan, an angiotensin receptor neprilysin inhibitor. Additionally, we looked into the device therapeutic approaches applied to these patients' care, specifically cardiac resynchronization therapy. Finally, we compared the outcomes of cardiac resynchronization therapy to those of a sophisticated medical treatment strategy using the combination of sacubitril/valsartan, an angiotensin receptor neprilysin inhibitor.
分享此文章
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 